Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9504668-B2
Publication Date
2016-11-29
Expiration Date
Abstract
The present invention provides a pharmaceutical composition for preventing and/or treating a epilepsy or epilepsy-related syndrome, for example an intractable epilepsy or its related syndrome such as drug-resistant epilepsy, comprising the phenyl alkyl carbamate compound as an active ingredient, and a use of the phenyl alkyl carbamate compound for preventing and/or treating epilepsy or epilepsy-related syndrome.
Core Innovation
The invention provides a method for treating an epilepsy or an epilepsy-related syndrome in a subject in need thereof by administering a pharmaceutically effective amount of a pharmaceutical composition. The pharmaceutical composition comprises a compound represented by Chemical Formula I or a pharmaceutically acceptable salt thereof as an active ingredient.
Chemical Formula I defines X as a halogen, with n being an integer from 1 to 5 and X the same or different when n is 2 or larger. R1 is a linear or branched C1-C4 alkyl group, and A and B are each selected from allyl, a C1-C19 linear or branched alkyl group, a C2-C8 alkoxy alky ether group, or a carbamoyl derivative.
The formula further includes R2 and R3, which may be the same as or different from each other and are independently selected from hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, and a benzyl group. The described scope includes refinements where the compound is present in a stereochemical form selected from racemate, enantiomer, diastereomer, a mixture of enantiomers, or a mixture of diastereomers.
Claims Coverage
The independent claim is a treatment method for epilepsy or an epilepsy-related syndrome using a pharmaceutical composition containing a Chemical Formula I compound or a pharmaceutically acceptable salt. The claim coverage is centered on the treatment method and the Chemical Formula I structural definition, with dependent claims narrowing the epilepsy type, substituent options, and stereochemical forms.
Treating epilepsy or an epilepsy-related syndrome by Chemical Formula I
A method for treating an epilepsy or an epilepsy-related syndrome in a subject in need thereof by administering a pharmaceutically effective amount of a pharmaceutical composition comprising a compound represented by Chemical Formula I or a pharmaceutically acceptable salt thereof as an active ingredient.
Treating intractable epilepsy
The method is specifically for treating intractable epilepsy.
Intractable epilepsy category selection
The intractable epilepsy is selected from localization-related epilepsy, generalized epilepsy, or their syndromes.
Specific halogen and substituent constraints for Chemical Formula I
X is a halogen; n is 1 to 5; R1 is a linear or branched C1-C4 alkyl group; A and B are selected from allyl, C1-C19 linear or branched alkyl, C2-C8 alkoxy alky ether group, or a carbamoyl derivative; and R2 and R3 are independently hydrogen, a linear or branched alkyl group of C1-C4, a cycloalkyl group of C3-C8, or benzyl group.
Selected C2-C8 alkoxy alky ether substituent set
The C2-C8 alkoxy alky ether group is selected from MOM, MEM, THP, BOM, MTM, SEM, or EE.
Permitted stereochemical forms for the active compound
The compound is present in a stereochemical form selected from racemate, enantiomer, diastereomer, a mixture of enantiomers, or a mixture of diastereomers.
Overall, the claims cover administering a pharmaceutically effective amount of a pharmaceutical composition containing a Chemical Formula I compound or pharmaceutically acceptable salt to treat epilepsy or an epilepsy-related syndrome, with dependent claims narrowing the indication to intractable epilepsy and further defining allowable halogen, substituent, and stereochemical variants.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Treating an epilepsy or an epilepsy-related syndrome in a subject in need thereof by administering a pharmaceutical composition containing a Chemical Formula I compound or a pharmaceutically acceptable salt.
Treating intractable epilepsy.
Treating intractable epilepsy selected from localization-related epilepsy, generalized epilepsy, or their syndromes.
Interested in licensing this patent?